Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
Bristol-Myers Squibb,Nivolumab,"Non-small cell lung cancer, locally advanced or metastatic, 2nd line",Nivolumab,Community and Hospital,Oncology Agents and Immunosuppressants
